Welcome to the e-CCO Library Archive!

Filter:
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 ... 213 ()
1. Autophagy contributes to immune regulation through destabilization of the immunological synapse
Authors: M.E. Wildenberg, A.C.W. Vos, M. Duijvestein, A.P. Verhaar, C. Strisciuglio, G.R. van den Brink, D.W. Hommes
1. Functional consequences of a novel IL-10 receptor alpha mutation on innate and adaptive immunity in early-onset inflammatory bowel disease
Authors:

M.A. van Leeuwen1, S. Veenbergen1, R. Kersseboom2, L.F. de Ruiter1, H. Raatgeep1, D.J. Lindenbergh-Kortleve1, Y. Simons-Oosterhuis1, L. de Ridder1, G.J.A. Driessen3, J.C. Escher1, J.N. Samsom1, 1Erasmus Medical Centre – Sophia Children's Hospital, Dept. of Paediatric Gastroenterology, Rotterdam, 2Erasmus Medical Centre, Dept. of Clinical Genetics, Rotterdam, 3Erasmus Medical Centre, Dept. of Paediatric Infectious Disease and Immunology, Rotterdam, Netherlands

10. Indigenous Australians (IA) have a distinctive gut microbial profile compared to patients with inflammatory bowel disease (IBD) and non Indigenous controls
Authors:

G. Iyngkaran1, S. Kang2, C. McSweeney2, S. Sivanesan1, M. Morrison2, F. Macrae1, 1Royal Melbourne Hospital, Department of Colorectal Medicine and Genetics, Parkville, 2CSIRO, Livestock Industries, Brisbane, Australia

10. Inhibition of IL-17A by secukinumab is ineffective for Crohn's disease (CD)
Authors: W. Hueber1, B.E. Sands2, M. Vandemeulebroecke3, W. Reinisch4, P.D.R. Higgins5, J. Wehkamp6, B. Feagan7, M. Yao8, A.P. Bertolino1, S. Travis9
11. NKG2D activation drives Th17 response in Crohn's disease
Authors: B. Pariente1, I. Mocan1, M. Camus1, J. Ettersperger1, C. Baudry2, J. Gornet2, M. Lémann2, N. Dulphy1, A. Toubert1, M. Allez2
11. Vedolizumab induction therapy for patients with Crohn's disease and prior anti-tumour necrosis factor antagonist failure: a randomised, placebo-controlled, double-blind, multicentre trial
Authors:

B. Sands1, B. Feagan2, P. Rutgeerts3, J.-F. Colombel4, W. Sandborn5, R. Sy6, G. D'Haens7, S. Ben-Horin8, J. Xu9, I. Fox9, A. Parikh10, C. Milch9, S. Hanauer11, 1Mount Sinai School of Medicine, Division of Gastroenterology, New York, United States, 2Robarts Research Institute, University of Western Ontario, London, Canada, 3University of Leuven, Leuven, Belgium, 4Hôpital Huriez, Department of Hepatogastroenterology, Lille, France, 5University of California, San Diego Health System, San Diego, United States, 6University of Ottawa, Division of Gastroenterology, Department of Medicine, Ottawa, Canada, 7University of Amsterdam, Academic Medical Center, Amsterdam, Netherlands, 8Chaim Sheba Medical Center, Department of Gastroenterology, Tel-Aviv, Israel, 9Millennium Pharmaceuticals, Inc., Cambridge, United States, 10Takeda Pharmaceuticals, Inc., Chicago, United States, 11University of Chicago Medical Center, Section of Gastroenterology, Hepatology and Nutrition, Chicago, United States

12. Ciclosporin versus infliximab in acute severe ulcerative colitis refractory to intravenous steroids: A randomized study
Authors: D. Laharie1, A. Bourreille2, J. Branche3, M. Allez4, Y. Bouhnik5, J. Filippi6, F. Zerbib7, M. Nachury8, G. Savoye9, J. Moreau10, J. Delchier11, E. Ricart12, J. Cosnes13, A. López-Sanromán14, O. Dewit15, F. Carbonnel16, G. Bommelaer17, B. Coffin18, G. Van Assche19, M. Esteve20, M. Faarkila21, A. Perez22, J. Mary23, J. Colombel3, M. Lémann4
12. Pre-existing IgG antibodies to the Fab region of infliximab predict efficacy and safety in IBD patients naive to anti-TNF agents
Authors:

C. Steenholdt1, Y. Palarasah2, K. Bendtzen2, A. Teisner3, B. Teisner2, J. Brynskov1, C. Nielsen2, 1Herlev Hospital, Dept of Gastroenterology, Herlev, 2Rigshospitalet, University Hospital of Copenhagen, Institute for Inflammation Research, Dept. of Infectious Diseases and Rheumatology, Copenhagen, 3Odense Hospital, Dept of Medical Gastroenterology S, Odense, Denmark

13. Infliximab, azathioprine, or infliximab + azathioprine for treatment of moderate to severe ulcerative colitis: The UC SUCCESS trial
Authors: R. Panaccione1, S. Ghosh1, S. Middleton2, J.R.M. Velazquez3, I. Khalif4, L. Flint5, H.J. van Hoogstraten5, H. Zheng5, S. Danese6, P. Rutgeerts7
13. Prevalence of anemia in patients with inflammatory bowel disease during the first ten years from diagnosis – results from a population-based inception cohort, the IBSEN Study
Authors:

M.L. Hoivik1, W. Reinisch2, M. Cvancarova3, B. Moum1, 1Oslo University Hospital, Gastroenterology, Oslo, Norway, 2Medizinische Universität Wien, Klinische Abt. Gastroenterologie & Hepatologie, Wien, Austria, 3University of Oslo, Department of Biostatistics, Oslo, Norway

14. Incidence and phenotype at diagnosis in paediatric IBD patients – An ECCO-EpiCom study
Authors:

J. Burisch1, D. Duricova2, N. Pedersen1, R. Salupere3, E. Tsianos4, M. Martinato5, O. Tighineanu6, V. Hernandez7, P. Lakatos8, P. Munkholm1, On behalf of the EpiCom Northern Italy center based in Crema, Cremona, Firenze, Forlì, Padova and Reggio Emilia, Italy, 1Herlev University Hospital, Department of Gastroenterology, Copenhagen, Denmark, 2Charles University, IBD Center ISCARE, Prague, Czech Republic, 3Tartu University Hospital, Division of Endocrinology and Gastroenterology, Tartu, Estonia, 4University Hospital, 1st Division of Internal Medicine and Hepato-Gastroenterology Unit, Ioannina, Greece, 5On behalf of the EpiCom Northern Italy center based in Crema, Cremona, Firenze, Forlì, Padova and Reggio Emilia, Italy, 6Center of Mother and Child, Section of Pediatric Gastroenterology, Chisinau, Republic of Moldova, 7Complexo Hospitalario Universitario de Vigo, Gastroenterology Department, Vigo, Spain, 8Semmelweis University, 1st Department of Medicine, Budapest, Hungary

14. Infliximab for severe IV steroid-refractory ulcerative colitis: Can infliximab trough levels guide our management?
Authors: M. Ferrante1, V. Ballet1, V. Geskens2, S. Vermeire1, G. Van Assche1, A. Gils2, P. Rutgeerts1
15. Risk of squamous and basal cell carcinomas in patients with inflammatory bowel disorders exposed to thiopurines: The Cesame National Cohort Study
Authors: L. Peyrin-Biroulet1, K. Khosrotehrani2, F. Carrat3, A. Bouvier4, J. Chevaux1, F. Carbonnel5, J. Colombel6, J. Dupas7, P. Godeberge8, J. Hugot9, M. Lémann10, S. Nahon11, J. Sabaté12, G. Tucat13, L. Beaugerie2
15. Serious infections and associated risk factors in patients receiving infliximab and immunotherapies for children with inflammatory bowel disease: DEVELOP registry data
Authors:

R. Baldassano1, R. Colletti2, S. Cucchiara3, M. Dubinsky4, J. Escher5, W. Faubion6, J. Fell7, B. Gold8, A. Griffiths9, J. Hyams10, S. Koletzko11, S. Kugathasan12, J. Markowitz13, F.M. Ruemmele14, G. Veereman15, P. Callegari16, M. Molenda16, K.L. Tang17, R. Wright16, H. Winter18, 1Children's Hospital of Philadelphia, United States, 2University of Vermont, United States, 3University of Rome, Italy, 4Cedars-Sinai Medical Center, United States, 5Erasmus MC-Sophia Children's Hospital, Netherlands, 6Mayo Clinic, United States, 7Chelsea and Westminster Hospital, United Kingdom, 8Children's Center for Digestive Healthcare Pediatric Gastroenterology, United States, 9Hospital for Sick Children, Canada, 10Connecticut Children's Medical Center, United States, 11Ludwig Maximilians University, Germany, 12Emory University School of Medicine, United States, 13Cohen Children's Medical Center of New York, United States, 14Hôpital Necker-Enfants Malades, France, 15KCE-Belgian Health Care Knowledge Centre, Belgium, 16Janssen Services, LLC, United States, 17Janssen Biotech, Inc, United States, 18MassGeneral Hospital for Children, United States

16. 52-week clinical efficacy with adalimumab in patients with moderately to severely active ulcerative colitis who failed corticosteroids and/or immunosuppressants
Authors: W. Reinisch1, W.J. Sandborn2, A. Kumar3, P.F. Pollack3, A. Lazar4, R. Thakkar3
16. Relationships between clinical remission, C-reactive protein normalization and mucosal healing in Crohn's disease: analyses from the SONIC trial
Authors:

L. Peyrin-Biroulet1, W. Reinisch2, J.-F. Colombel3, G.J. Mantzaris4, A. Kornbluth5, R. Diamond6, P. Rutgeerts7, K.L. Tang6, F.J. Cornillie8, W. Sandborn9, 1University Hospital of Nancy-Brabois, France, 2Universitätsklinik für Innere Medizin IV, Austria, 3Hôpital Claude Huriez, France, 3Evangelismos Hospital, Greece, 5Mount Sinai Medical Center, United States, 6Janssen Biotech, Inc, United States, 7University Hospital, Gasthuisberg, Belgium, 8Janssen Biotechnology BV, Netherlands, 9University of California San Diego, United States

17. Long term evolution and impact of immunomodulator co-treatment and withdrawal on infliximab trough levels in 223 patients with Crohn's disease
17. Optimising the use of faecal calprotectin for early diagnosis of IBD in primary care
Authors:

O.M. Demir1, Z. Ahmed1, R.P.H. Logan1, 1Kings College Hospital, Gastroenterology, London, United Kingdom

18. Junctional adhesion molecule-A is a new key regulator in colitis associated colon cancer
18. The quality of care for inpatients with inflammatory bowel disease in the UK over a six year period
Authors:

L. Alrubaiy1, I. Arnott2, A. Protheroe3, M. Roughton3, J. Williams1, 1College of Medicine, Swansea University, Swansea, 2Western General Hospital, Edinburgh, 3Royal College of Physicians, London, United Kingdom

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 ... 213 ()